Recent studies have shown the ability to preferentially deliver nanoparticles to tumour cells by targeting overexpressed receptors in breast cancer cells, such as human epidermal growth factor receptor 2 (HER2) and folate-functionalised nanoparticles [15]. This evidence concerns the gene ERBB2 and neoplasm.